Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review
Curr Pharm Biotechnol. 2023 Mar 2. doi: 10.2174/1389201024666230302113110. Online ahead of print.ABSTRACTCOVID-19, an extremely transmissible and pathogenic viral disease, triggered a global pandemic that claimed lives worldwide. To date, there is no clear and fully effective treatment for COVID-19 disease. Nevertheless, the urgency to discover treatments that can turn the tide has led to the development of a variety of preclinical drugs that are potential candidates for probative results. Although most of these supplementary drugs are constantly being tested in clinical trials against COVID-19, recognized organizations ha...
Source: Current Pharmaceutical Biotechnology - March 2, 2023 Category: Biotechnology Authors: Yashumati Ratan Aishwarya Rajput Vivek Jain Dinesh Kumar Mishra Rupesh K Gautam Ashutosh Pareek Source Type: research
[ASAP] Stability and Mechanical Properties of Darunavir Isostructural Solvates: An Experimental and Computational Study
Crystal Growth& DesignDOI: 10.1021/acs.cgd.3c00057 (Source: Crystal Growth and Design)
Source: Crystal Growth and Design - February 28, 2023 Category: Chemistry Authors: Kaxi Yu, Jie Shen, Jiyong Liu, Guping Tang, and Xiurong Hu Source Type: research
Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study
Biomed Pharmacother. 2023 Feb 21;161:114427. doi: 10.1016/j.biopha.2023.114427. Online ahead of print.ABSTRACTApproximately two-thirds of Romanian HIV patients were parenterally infected with the F subtype of HIV in early childhood. They are now in the context of immunological aging, with immunosuppression posing an additional challenge in developing the most effective and well-tolerated regimens. The risk of an improper immune recovery is higher in these patients than in newly diagnosed patients. The primary goal of this retrospective study was to conduct a comparative analysis of the immune recovery, measured at three ti...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 23, 2023 Category: Drugs & Pharmacology Authors: Ruxandra-Cristina Marin Simona Gabriela Bungau Delia Mirela Tit Paul Andrei Negru Andrei-Flavius Radu Radu Dumitru Moleriu Source Type: research
Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study
Biomed Pharmacother. 2023 Feb 21;161:114427. doi: 10.1016/j.biopha.2023.114427. Online ahead of print.ABSTRACTApproximately two-thirds of Romanian HIV patients were parenterally infected with the F subtype of HIV in early childhood. They are now in the context of immunological aging, with immunosuppression posing an additional challenge in developing the most effective and well-tolerated regimens. The risk of an improper immune recovery is higher in these patients than in newly diagnosed patients. The primary goal of this retrospective study was to conduct a comparative analysis of the immune recovery, measured at three ti...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 23, 2023 Category: Drugs & Pharmacology Authors: Ruxandra-Cristina Marin Simona Gabriela Bungau Delia Mirela Tit Paul Andrei Negru Andrei-Flavius Radu Radu Dumitru Moleriu Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
CONCLUSIONS: The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression.PMID:36809850 | DOI:10.1016/j.bjid.2023.102757 (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - February 22, 2023 Category: Infectious Diseases Authors: Elaine Monteiro Matsuda Ivana Barros Campos Isabela Penteriche de Oliveira Daniela Rodrigues Colpas Giselle Ibete Silva L ópez-Lopes Victor Oliveira Chiavegato Lu ís Fernando de Macedo Brígido Source Type: research
